TABLE 1.
Demographic, clinical, and laboratory parameters of subjects included in the study at admission
| Variables | HC (N = 292; 72%) | COVID‐19 (N = 111; 28%) | p‐Value |
|---|---|---|---|
| Age | 46.0 (35.0, 53.0) | 59.0 (48.7, 66.0) | <0.0001 |
| Ethnicity | |||
| White‐European | 284 (97.2) | 97 (87.4) | N/A |
| Latin‐American | 7 (2.4) | 9 (8.1) | N/A |
| African | 0 (0.0) | 4 (3.6) | N/A |
| Asian‐Far East Asian | 1 (0.4) | 1 (0.9) | N/A |
| BMI | 25.2 (23.52, 27.58) | 27.81 (25.13, 30.42) | <0.0001 |
| Comorbidities | |||
| CCI | 0.0 (0.0, 0.0) | 0.0 (0.0, 1.0) | 0.0094 |
| CCI‐age | 0.0 (0.0, 1.0) | 2.0 (0.0, 3.0) | <0.0001 |
| CCI (score) | |||
| 0 | 292 (100) | 63 (53.3) | <0.0001 |
| 1 | 0.0 (0.0) | 26 (23.6) | <0.0001 |
| ≥ 2 | 0.0 (0.0) | 22 (0.2) | <0.0001 |
| Arterial hypertension | 32 (11) | 41 (37.3) | <0.0001 |
| CRP (mg/L) | 38 (13%) | 39 (35%) | 0.001 |
| Laboratory parameters | |||
| WBC (count/ul) | 5.8 (4.9, 6.5) | 7.2 (5.6, 9.9) | <0.0001 |
| Neutrophils (count/ul) | 3.1 (2.5, 3.7) | 5.6 (4.1, 7.7) | <0.0001 |
| Lymphocytes (count/ul) | 1.8 (1.5, 2.1) | 1.0 (0.7, 1.4) | <0.0001 |
| Hemoglobin (g/dl) | 15.1 (14.4, 15.6) | 13.55 (12.1, 15) | <0.0001 |
| IL‐6 (pg/ml) | 2.5 (2.5, 4.0) | 47.2 (18.35, 106.5) | <0.0001 |
| IL‐10 (pg/ml) | 3.0 (1.5, 3.0) | 6.0 (3.0, 12.6) | <0.0001 |
| HLA‐G5 (ng/ml) | 178.0 (100.5, 275.7) | 315.5 (174.4, 410.0) | <0.0001 |
| tT (nmol/L) | 10.6 (8.1, 13.9) | 2.4 (0.9, 4.2) | <0.0001 |
| E2 (pg/ml) | 22.9 (18.9, 43.1) | 34.5 (18.2, 43.1) | <0.0001 |
Continuous variables are presented as medians (interquartile range); categorical variables are presented as frequency (%). For each variable, the two‐tailed Mann‐Whitney test and Chi Square test were used for testing the difference between groups. Statistically significant p‐values are indicated in bold.
Abbreviations: BMI, Body Mass Index; CCI, Charlson Comorbidity Index; CRP, C‐reactive protein; E2, 17β‐estradiol; HC, healthy controls; tT, total testosterone; WBC, white blood cells.